Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
L-697, 661 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| L-697,661 | DRUG | - |
| Zidovudine | DRUG | - |
Inclusion Criteria Patients must have: * HIV infection. Prior Medication: Included: * Patients in Part 1 must have received no previous zidovudine (AZT) or a stable dose of at least 500 mg/day without evidence of toxicity. * Patients in Part 2 must have received no previous AZT or = or \> 300 mg...
Top 20 of 28 competitors
L-697,661 is an investigational small molecule being studied for the treatment of HIV Infections. It is in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated for its safety and pharmacokinetic profile in patients with HIV.
L-697,661 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical research to evaluate the drug's potential in treating HIV Infections.
L-697,661 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved for commercial use. The drug is being studied in early-stage clinical trials to assess its safety, tolerability, and pharmacokinetics in patients with HIV Infections.
L-697,661 has one completed clinical trial registered as NCT00000628, titled "A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine." This Phase 1 study enrolled 27 participants with HIV Infections in the United States and was not randomized or blinded.
The mechanism of action for L-697,661 has not been disclosed in available clinical trial information. The drug is being studied as a small molecule for HIV Infections, but its specific molecular target has not been publicly specified in the trial data.